CARDIOVASCULAR JOURNAL OF AFRICA • Volume 35, No 2, May – August 2024 74 AFRICA receiving colloid or crystalloid priming of cardiopulmonary bypass. Br J Anaesth 1997; 79(3): 311–316. 15. London MJ. Pro: colloids should be added to the pump prime. J Cardiothorac Anesth 1990; 4(3): 401–405. 16. D’Ambra MN, Philbin DM. Con: colloids should not be added to the pump prime. J Cardiothorac Anesth 1990; 4(3): 406–408. 17. Verheij J, van Lingen A, Beishuizen A, Christiaans HM, de Jong JR, Girbes AR, et al. Cardiac response is greater for colloid than saline fluid loading after cardiac or vascular surgery. Intensive Care Med 2006; 32(7): 1030–1038. 18. Zdolsek JH, Bergek C, Lindahl TL, Hahn RG. Colloid osmotic pressure and extravasation of plasma proteins following infusion of Ringer’s acetate and hydroxyethyl starch 130/0.4. Acta Anaesthesiol Scand 2015; 59(10): 1303–1310. 19. Eising GP, Niemeyer M, Gunther T, Tassani P, Pfauder M, Schad H, et al. Does a hyperoncotic cardiopulmonary bypass prime affect extravascular lung water and cardiopulmonary function in patients undergoing coronary artery bypass surgery? Eur J Cardiothorac Surg 2001; 20(2): 282–289. 20. Scott DA, Hore PJ, Cannata J, Masson K, Treagus B, Mullaly J. A comparison of albumin, polygeline and crystalloid priming solutions for cardiopulmonary bypass in patients having coronary artery bypass graft surgery. Perfusion 1995; 10(6): 415–424. 21. Hanasand M, Omdal R, Norheim KB, Goransson LG, Brede C, Jonsson G. Improved detection of advanced oxidation protein products in plasma. Clin Chim Acta 2012; 413(9–10): 901–906. 22. Bar-Or D, Rael LT, Bar-Or R, Slone DS, Mains CW, Rao NK, et al. The cobalt–albumin binding assay: insights into its mode of action. Clin Chim Acta 2008; 387(1–2): 120–127. 23. Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem 1968; 25(1): 192–205. 24. Sydow G. A simplified quick method for determination of sialic acid in serum. Biomed Biochim Acta 1985; 44(11–12): 1721–1723. 25. Harboe M. A method for determination of hemoglobin in plasma by nearultraviolet spectrophotometry. Scand J Clin Lab Invest 1959; 11: 66–70. 26. Lomivorotov VV, Fominskiy EV, Efremov SM, Nepomniashchikh VA, Lomivorotov VN, Chernyavskiy AM, et al. Hypertonic solution decreases extravascular lung water in cardiac patients undergoing cardiopulmonary bypass surgery. J Cardiothorac Vasc Anesth 2013; 27(2): 273–282. 27. Olthof CG, Jansen PG, de Vries JP, Kouw PM, Eijsman L, de Lange JJ, et al. Interstitial fluid volume during cardiac surgery measured by means of a non-invasive conductivity technique. Acta Anaesthesiol Scand 1995; 39(4): 508–512. 28. Starling EH. On the absorption of fluids from the connective tissue spaces. J Physiol 1896; 19(4): 312–326. 29. Levick JR. Revision of the Starling principle: new views of tissue fluid balance. J Physiol 2004; 557(Pt 3): 704. 30. Beukers AM, de Ruijter JAC, Loer SA, Vonk A, Bulte CSE. Effects of crystalloid and colloid priming strategies for cardiopulmonary bypass on colloid oncotic pressure and haemostasis: a meta-analysis. Interact Cardiovasc Thorac Surg 2022; 35(3). 31. Sade RM, Stroud MR, Crawford FA, Jr., Kratz JM, Dearing JP, Bartles DM. A prospective randomized study of hydroxyethyl starch, albumin, and lactated Ringer’s solution as priming fluid for cardiopulmonary bypass. J Thorac Cardiovasc Surg 1985; 89(5): 713–722. 32. Tiryakioglu O, Yildiz G, Vural H, Goncu T, Ozyazicioglu A, Yavuz S. Hydroxyethyl starch versus Ringer solution in cardiopulmonary bypass prime solutions (a randomized controlled trial). J Cardiothorac Surg 2008; 3: 45. 33. Gurbuz HA, Durukan AB, Salman N, Tavlasoglu M, Durukan E, Ucar HI, et al. Hydroxyethyl starch 6%, 130/0.4 vs. a balanced crystalloid solution in cardiopulmonary bypass priming: a randomized, prospective study. J Cardiothorac Surg 2013; 8: 71. 34. Choi YS, Shim JK, Hong SW, Kim JC, Kwak YL. Comparing the effects of 5% albumin and 6% hydroxyethyl starch 130/0.4 on coagulation and inflammatory response when used as priming solutions for cardiopulmonary bypass. Minerva Anestesiol 2010; 76(8): 584–591. 35. Liou HL, Shih CC, Chao YF, Lin NT, Lai ST, Wang SH, et al. Inflammatory response to colloids compared to crystalloid priming in cardiac surgery patients with cardiopulmonary bypass. Chin J Physiol 2012; 55(3): 210–218. 36. Tseke P, Grapsa E, Stamatelopoulos K, Samouilidou E, Rammos G, Papamichael C, et al. Correlations of sialic acid with markers of inflammation, atherosclerosis and cardiovascular events in hemodialysis patients. Blood Purif 2008; 26(3): 261–266. 37. Jinghua L, Tie Z, Ping W, Yongtong C. The relationship between serum sialic acid and high-sensitivity C-reactive protein with prehypertension. Med Sci Monit 2014; 20: 551–555. Fewer people may need statins to prevent heart disease: US study A new way of determining heart disease risk could slash the numbers of people who are prescribed statins, suggests a recent study, although doctors warn that more information is needed and patients shouldn’t stop taking their medications. Statins are used by millions of people as protection against high levels of low-density lipoprotein (LDL) cholesterol, one of the causes of cardiovascular disease. Doctors prescribe the daily pills based on 2013 guidelines from the American Heart Association (AHA) and the American College of Cardiology (ACC), which estimate risk based on age, diabetes, blood pressure and other factors, reports NBS News. In the latest study, Dr Tim Anderson, an assistant professor of medicine at the University of Pittsburgh, and colleagues analysed the potential impact of a new heart disease risk calculator dubbed PREVENT, released by the AHA last year, and compared estimates with older guidelines. The data were from 3 785 adults aged 40 to 75 years, all of whom were participants in the National Health and Nutrition Examination Survey (NHANES). The new calculator was developed to give a more accurate assessment of a person’s likelihood of developing heart disease by incorporating newly recognised risk factors such as kidney disease and obesity. The researchers found that among the participants, the 10-year risk of developing heart disease determined with the new tool was about half that estimated with the previous one, according to the report published in J Am Med Assoc Internal Medicine. Using PREVENT to calculate the 10-year risk for developing heart disease, the researchers determined that some 40% fewer people would have met the criteria for a statin prescription. continued on page 81…
RkJQdWJsaXNoZXIy NDIzNzc=